MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced dosing of the first participant in its Phase 1 trial of MBX 4291, the Company’s Precision Endocrine Peptide™ ...